Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease

BackgroundSteroid-resistant (SR) lower gastrointestinal (LGI) tract graft-versus-host disease (GVHD) is the predominant cause of morbidity and mortality from GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of vedolizumab in the treatment of SR-LGI acute GVHD (aGVH...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Zicheng Gao, Zhiping Fan, Zhi Liu, Xu Ye, Yunxin Zeng, Li Xuan, Fen Huang, Ren Lin, Jing Sun, Qifa Liu, Na Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	HSCT vedolizumab basiliximab steroid-refractory GVHD lower intestinal GVHD α4β7
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1408211/full